aTyr Pharma, Inc.
$ 0.85
2.76%
17 Apr - close price
- Market Cap 81,432,000 USD
- Current Price $ 0.85
- High / Low $ 0.87 / 0.83
- Stock P/E N/A
- Book Value 0.69
- EPS -0.80
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.51 %
- ROE -1.08 %
- 52 Week High 7.29
- 52 Week Low 0.64
About
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$4.36
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-06 | 2025-08-07 | 2025-04-30 | 2025-03-12 | 2024-11-07 | 2024-08-07 | 2024-05-02 | 2024-03-14 | 2023-11-09 | 2023-08-09 | 2023-05-09 |
| Reported EPS | -0.14 | -0.26 | -0.22 | -0.17 | -0.1809 | -0.2277 | -0.2256 | -0.23 | -0.25 | -0.2 | -0.22 | -0.29 |
| Estimated EPS | -0.183 | -0.17 | -0.1845 | -0.19 | -0.226 | -0.22 | -0.24 | -0.24 | -0.24 | -0.2 | -0.28 | -0.29 |
| Surprise | 0.043 | -0.09 | -0.0355 | 0.02 | 0.0451 | -0.0077 | 0.0144 | 0.01 | -0.01 | 0 | 0.06 | 0 |
| Surprise Percentage | 23.4973% | -52.9412% | -19.2412% | 10.5263% | 19.9558% | -3.5% | 6% | 4.1667% | -4.1667% | 0% | 21.4286% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.16 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATYR
2026-04-14 21:10:07
aTyr Pharma, a clinical-stage biopharmaceutical company, is developing efzofitimod for pulmonary sarcoidosis, a rare inflammatory lung disease. The stock represents a high-risk, high-reward investment due to the late-stage trials and potential catalysts. Analysts maintain a generally positive stance, citing efzofitimod's potential for substantial upside if Phase 3 results, expected in late 2025 or early 2026, are positive.
2026-04-07 08:08:00
This article provides a head-to-head comparison of two small-cap biopharmaceutical companies, Silo Pharma (NASDAQ:SILO) and aTyr Pharma (NASDAQ:ATYR), for investors interested in the biotech sector. It evaluates them based on profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings, and risk. The goal is to help investors determine which stock might be a better fit for their portfolio.
2026-04-01 10:40:00
This article provides a technical analysis and stock price forecast for aTyr Pharma Inc (ATYR), indicating a "Strong Buy" consensus based on various technical indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and performance relative to moving averages, offering insights for potential investors.
2026-03-27 19:40:02
This article announces an ARS SEC filing by aTYR PHARMA INC (ATYR) on March 26, 2026, detailing that the filing impact is low and the sentiment is neutral. It provides a link to view the PDF document on SEC EDGAR and lists recent news and SEC filings for the company. The article also includes key stock data for ATYR.
2026-03-26 20:09:03
Vanguard has filed an amended Schedule 13G for aTyr Pharma (ATYR), reporting 0 shares beneficially owned and 0% of common stock. This change is due to an internal realignment on January 12, 2026, where Vanguard's subsidiaries will now report beneficial ownership separately, as per SEC guidance. This is an administrative reclassification, not an economic disposition, and subsequent filings from Vanguard affiliates are expected to show their individual holdings.
2026-03-25 06:10:56
aTyr Pharma, Inc. (NASDAQ:ATYR) has received a consensus "Hold" recommendation from seven analysts, with an average 12-month price target of $25.67. The clinical-stage biotech, focused on rare disease therapies, recently reported better-than-expected EPS and analysts predict -0.91 EPS for the current fiscal year. Institutional investors hold a significant 61.72% of the company's stock, which recently traded down 4.6% at $0.79.
